Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy

NCT07266181 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Air Force Medicial University as lead sponsor.

NCT NCT07266181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy
Lead sponsor
The First Affiliated Hospital of Air Force Medicial University
Phase
Phase 1
Overall status
Recruiting
Start date
December 8, 2025
Completion date
July 31, 2028
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory membranous nephropathy